Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer

Shogen Ohya, Motowo Mizuno, Mikihiro Kawada, Junichirou Nasu, Hiroyuki Okada, Hiroyuki Shimomura, Kazuhide Yamamoto, Teizo Fujita, Takao Tsuji

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have previously developed an enzyme-linked immunosorbent assay (ELISA) to measure stool decay-accelerating factor (DAF) and found that stool DAF concentrations were significantly elevated in patients with colorectal cancer, suggesting that the measurement of stool DAF may be valuable for the detection of colorectal cancer. In order to refine the assay for the measurement of stool DAF, we investigated 1) effects of centrifugation of stool samples, 2) effects of detergents, and 3) adequate combination of various anti-DAF monoclonal antibodies for the ELISA system using only monoclonal antibodies. We found that high-speed centrifugation could be omitted and that only the removal of large undigested food residues by centrifugation of short duration in a low-speed benchtop microcentrifuge sufficed to adequately prepare the stool samples. Addition of 2 detergents, octyl β-glucoside and sodium deoxycholate, known to solubilize glycosyl-phosphatidylinositol-anchored proteins such as DAF, did not influence stool DAF values. By using 2 mouse anti-DAF monoclonal antibodies (clone 4F11 and 1C6), we were able to achieve a stable ELISA for the measurement of stool DAF using a uniform source of antibodies. The results should allow us to consistently apply the DAF assay for routine use in the detection of colorectal cancer.

Original languageEnglish
Pages (from-to)171-176
Number of pages6
JournalActa Medica Okayama
Volume56
Issue number4
Publication statusPublished - 2002

Fingerprint

CD55 Antigens
Colorectal Neoplasms
Assays
Immunosorbents
Centrifugation
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies
Detergents
Enzymes
Glycosylphosphatidylinositols
Deoxycholic Acid
Clone Cells

Keywords

  • Colorectal cancer
  • Decay-accelerating factor (DAF)
  • Enzyme-linked immunosorbent assay (ELISA)
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ohya, S., Mizuno, M., Kawada, M., Nasu, J., Okada, H., Shimomura, H., ... Tsuji, T. (2002). Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer. Acta Medica Okayama, 56(4), 171-176.

Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer. / Ohya, Shogen; Mizuno, Motowo; Kawada, Mikihiro; Nasu, Junichirou; Okada, Hiroyuki; Shimomura, Hiroyuki; Yamamoto, Kazuhide; Fujita, Teizo; Tsuji, Takao.

In: Acta Medica Okayama, Vol. 56, No. 4, 2002, p. 171-176.

Research output: Contribution to journalArticle

Ohya, S, Mizuno, M, Kawada, M, Nasu, J, Okada, H, Shimomura, H, Yamamoto, K, Fujita, T & Tsuji, T 2002, 'Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer', Acta Medica Okayama, vol. 56, no. 4, pp. 171-176.
Ohya, Shogen ; Mizuno, Motowo ; Kawada, Mikihiro ; Nasu, Junichirou ; Okada, Hiroyuki ; Shimomura, Hiroyuki ; Yamamoto, Kazuhide ; Fujita, Teizo ; Tsuji, Takao. / Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer. In: Acta Medica Okayama. 2002 ; Vol. 56, No. 4. pp. 171-176.
@article{5f4ea335e29f4bffb4589ce212e6203d,
title = "Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer",
abstract = "We have previously developed an enzyme-linked immunosorbent assay (ELISA) to measure stool decay-accelerating factor (DAF) and found that stool DAF concentrations were significantly elevated in patients with colorectal cancer, suggesting that the measurement of stool DAF may be valuable for the detection of colorectal cancer. In order to refine the assay for the measurement of stool DAF, we investigated 1) effects of centrifugation of stool samples, 2) effects of detergents, and 3) adequate combination of various anti-DAF monoclonal antibodies for the ELISA system using only monoclonal antibodies. We found that high-speed centrifugation could be omitted and that only the removal of large undigested food residues by centrifugation of short duration in a low-speed benchtop microcentrifuge sufficed to adequately prepare the stool samples. Addition of 2 detergents, octyl β-glucoside and sodium deoxycholate, known to solubilize glycosyl-phosphatidylinositol-anchored proteins such as DAF, did not influence stool DAF values. By using 2 mouse anti-DAF monoclonal antibodies (clone 4F11 and 1C6), we were able to achieve a stable ELISA for the measurement of stool DAF using a uniform source of antibodies. The results should allow us to consistently apply the DAF assay for routine use in the detection of colorectal cancer.",
keywords = "Colorectal cancer, Decay-accelerating factor (DAF), Enzyme-linked immunosorbent assay (ELISA), Monoclonal antibodies",
author = "Shogen Ohya and Motowo Mizuno and Mikihiro Kawada and Junichirou Nasu and Hiroyuki Okada and Hiroyuki Shimomura and Kazuhide Yamamoto and Teizo Fujita and Takao Tsuji",
year = "2002",
language = "English",
volume = "56",
pages = "171--176",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer

AU - Ohya, Shogen

AU - Mizuno, Motowo

AU - Kawada, Mikihiro

AU - Nasu, Junichirou

AU - Okada, Hiroyuki

AU - Shimomura, Hiroyuki

AU - Yamamoto, Kazuhide

AU - Fujita, Teizo

AU - Tsuji, Takao

PY - 2002

Y1 - 2002

N2 - We have previously developed an enzyme-linked immunosorbent assay (ELISA) to measure stool decay-accelerating factor (DAF) and found that stool DAF concentrations were significantly elevated in patients with colorectal cancer, suggesting that the measurement of stool DAF may be valuable for the detection of colorectal cancer. In order to refine the assay for the measurement of stool DAF, we investigated 1) effects of centrifugation of stool samples, 2) effects of detergents, and 3) adequate combination of various anti-DAF monoclonal antibodies for the ELISA system using only monoclonal antibodies. We found that high-speed centrifugation could be omitted and that only the removal of large undigested food residues by centrifugation of short duration in a low-speed benchtop microcentrifuge sufficed to adequately prepare the stool samples. Addition of 2 detergents, octyl β-glucoside and sodium deoxycholate, known to solubilize glycosyl-phosphatidylinositol-anchored proteins such as DAF, did not influence stool DAF values. By using 2 mouse anti-DAF monoclonal antibodies (clone 4F11 and 1C6), we were able to achieve a stable ELISA for the measurement of stool DAF using a uniform source of antibodies. The results should allow us to consistently apply the DAF assay for routine use in the detection of colorectal cancer.

AB - We have previously developed an enzyme-linked immunosorbent assay (ELISA) to measure stool decay-accelerating factor (DAF) and found that stool DAF concentrations were significantly elevated in patients with colorectal cancer, suggesting that the measurement of stool DAF may be valuable for the detection of colorectal cancer. In order to refine the assay for the measurement of stool DAF, we investigated 1) effects of centrifugation of stool samples, 2) effects of detergents, and 3) adequate combination of various anti-DAF monoclonal antibodies for the ELISA system using only monoclonal antibodies. We found that high-speed centrifugation could be omitted and that only the removal of large undigested food residues by centrifugation of short duration in a low-speed benchtop microcentrifuge sufficed to adequately prepare the stool samples. Addition of 2 detergents, octyl β-glucoside and sodium deoxycholate, known to solubilize glycosyl-phosphatidylinositol-anchored proteins such as DAF, did not influence stool DAF values. By using 2 mouse anti-DAF monoclonal antibodies (clone 4F11 and 1C6), we were able to achieve a stable ELISA for the measurement of stool DAF using a uniform source of antibodies. The results should allow us to consistently apply the DAF assay for routine use in the detection of colorectal cancer.

KW - Colorectal cancer

KW - Decay-accelerating factor (DAF)

KW - Enzyme-linked immunosorbent assay (ELISA)

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=0036689967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036689967&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 171

EP - 176

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -